PARP1 and B-cell chronic lymphocytic leukemia: We found that sensitivity to talazoparib was independent of the ATM functional status of the cells, in contrast to previous studies showing that ATM dysfunctional CLL cells were more sensitive to the PARP inhibitor, olaparib [12].